Decoy Therapeutics Inc. (DCOY)
Market Price (6/24/2026): $6.2 | Market Cap: $3.3 MilSector: Health Care | Industry: Biotechnology
Decoy Therapeutics Inc. (DCOY)
Market Price (6/24/2026): $6.2Market Cap: $3.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -245% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Oncology Treatments, Show more. | Weak multi-year price returns2Y Excs Rtn is -134%, 3Y Excs Rtn is -166% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -413% High stock price volatilityVol 12M is 145% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -245% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Oncology Treatments, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -134%, 3Y Excs Rtn is -166% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -413% |
| High stock price volatilityVol 12M is 145% |
Qualitative Assessment
AI Analysis | Feedback
Decoy Therapeutics Inc. (DCOY) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. Decoy Therapeutics Inc. issued a "going concern" warning and reported increased financial losses in its fiscal Q1 2026, which ended on March 31, 2026. The company reported a net loss of $2.22 million for the quarter, an increase from a $1.71 million net loss in fiscal Q1 2025. As a pre-revenue company, Decoy disclosed "substantial doubt" about its ability to continue as a going concern, with its cash, cash equivalents, and restricted cash of $7.82 million as of March 31, 2026, expected to fund operations only into late 2026.
2. The company's pre-clinical stage and extended timeline to potential market entry contributed to investor uncertainty. Decoy Therapeutics remains a pre-clinical biotechnology company, with its lead D-MAV™ candidate targeting first clinical entry in 2027. The company's valuation is heavily dependent on the scientific performance of its IMP³ACT™ platform and its ability to advance candidates into human studies, representing a long and capital-intensive development path without immediate revenue prospects.
Show more
Decoy Therapeutics Inc. (DCOY) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. Decoy Therapeutics Inc. issued a "going concern" warning and reported increased financial losses in its fiscal Q1 2026, which ended on March 31, 2026. The company reported a net loss of $2.22 million for the quarter, an increase from a $1.71 million net loss in fiscal Q1 2025. As a pre-revenue company, Decoy disclosed "substantial doubt" about its ability to continue as a going concern, with its cash, cash equivalents, and restricted cash of $7.82 million as of March 31, 2026, expected to fund operations only into late 2026.
2. The company's pre-clinical stage and extended timeline to potential market entry contributed to investor uncertainty. Decoy Therapeutics remains a pre-clinical biotechnology company, with its lead D-MAV™ candidate targeting first clinical entry in 2027. The company's valuation is heavily dependent on the scientific performance of its IMP³ACT™ platform and its ability to advance candidates into human studies, representing a long and capital-intensive development path without immediate revenue prospects.
3. A 1-for-12 reverse stock split was implemented in March 2026 to maintain Nasdaq compliance, often signaling underlying financial distress. Decoy Therapeutics Inc. executed a 1-for-12 reverse stock split on March 6, 2026, effective March 9, 2026, to meet Nasdaq's minimum $1.00 bid price requirement and avoid delisting. While this was a technical adjustment to maintain its listing status, such actions are frequently viewed negatively by the market, highlighting fundamental challenges and rarely leading to sustained positive stock momentum without significant operational improvements.
4. Market sentiment remained negative despite several "positive" company announcements, indicating a lack of investor confidence in these developments. Decoy Therapeutics made various strategic and partnership announcements since February 28, 2026, including a collaboration with hVIVO to advance its lead D-MAV™ candidate into clinical development on June 1, 2026, and the nomination of a global biopharma executive to its Board of Directors on June 3, 2026. However, these updates often produced mixed reactions and were followed by negative price moves, suggesting investors did not perceive them as sufficient to overcome the company's core financial and clinical development risks.
Show less
Stock Movement Drivers
Fundamental Drivers
The -26.6% change in DCOY stock from 2/28/2026 to 6/23/2026 was primarily driven by a -92.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 6232026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.17 | 6.00 | -26.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -92.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/23/2026| Return | Correlation | |
|---|---|---|
| DCOY | -26.6% | |
| Market (SPY) | 7.2% | 16.9% |
| Sector (XLV) | -4.6% | 7.4% |
Fundamental Drivers
The -46.8% change in DCOY stock from 11/30/2025 to 6/23/2026 was primarily driven by a -92.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 6232026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.28 | 6.00 | -46.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -92.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/23/2026| Return | Correlation | |
|---|---|---|
| DCOY | -46.8% | |
| Market (SPY) | 8.0% | 15.9% |
| Sector (XLV) | -2.7% | 7.9% |
Fundamental Drivers
The -95.6% change in DCOY stock from 5/31/2025 to 6/23/2026 was primarily driven by a -98.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312025 | 6232026 | Change |
|---|---|---|---|
| Stock Price ($) | 137.32 | 6.00 | -95.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -98.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2025 to 6/23/2026| Return | Correlation | |
|---|---|---|
| DCOY | -95.6% | |
| Market (SPY) | 25.9% | 7.5% |
| Sector (XLV) | 16.8% | -2.6% |
Fundamental Drivers
The -99.7% change in DCOY stock from 5/31/2023 to 6/23/2026 was primarily driven by a -99.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312023 | 6232026 | Change |
|---|---|---|---|
| Stock Price ($) | 2030.40 | 6.00 | -99.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -99.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2023 to 6/23/2026| Return | Correlation | |
|---|---|---|
| DCOY | -99.7% | |
| Market (SPY) | 82.4% | -0.1% |
| Sector (XLV) | 25.1% | -3.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DCOY Return | -46% | -88% | -58% | -65% | -98% | -19% | -100% |
| Peers Return | 43% | -20% | 3% | 78% | -33% | -9% | 27% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| DCOY Win Rate | 25% | 17% | 25% | 33% | 33% | 33% | |
| Peers Win Rate | 46% | 50% | 46% | 58% | 75% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| DCOY Max Drawdown | -84% | -92% | -84% | -78% | -99% | -71% | |
| Peers Max Drawdown | -41% | -46% | -34% | -26% | -59% | -39% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ATYR, AVLN, CNXU, COAG.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/23/2026 (YTD)
How Low Can It Go
| Event | DCOY | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -44.2% | -7.8% |
| % Gain to Breakeven | 79.2% | 8.5% |
| Time to Breakeven | 8 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.1% | -33.7% |
| % Gain to Breakeven | 69.8% | 50.9% |
| Time to Breakeven | 56 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -50.0% | -19.2% |
| % Gain to Breakeven | 100.0% | 23.8% |
| Time to Breakeven | 109 days | 105 days |
In The Past
Decoy Therapeutics Inc.'s stock fell -44.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 79.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | DCOY | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -44.2% | -7.8% |
| % Gain to Breakeven | 79.2% | 8.5% |
| Time to Breakeven | 8 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.1% | -33.7% |
| % Gain to Breakeven | 69.8% | 50.9% |
| Time to Breakeven | 56 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -50.0% | -19.2% |
| % Gain to Breakeven | 100.0% | 23.8% |
| Time to Breakeven | 109 days | 105 days |
In The Past
Decoy Therapeutics Inc.'s stock fell -44.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 79.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Decoy Therapeutics Inc. (DCOY)
AI Analysis | Feedback
AI Analysis | Feedback
- Seclidemstat (SP-2577): A small molecular inhibitor undergoing Phase I/II clinical trials for advanced solid tumors and Ewing sarcoma.
- SP-3164: A small molecular protein degrader developed for treating hematological and solid tumors.
AI Analysis | Feedback
Decoy Therapeutics Inc. (DCOY), as a clinical-stage biotechnology company, is primarily focused on the development of epigenetic-based cancer treatments. Its lead candidates, Seclidemstat (SP-2577) and SP-3164, are currently in Phase I/II clinical trials and have not yet received regulatory approval for commercial sale.
Given that its drug candidates are still in the developmental and clinical trial stages, Decoy Therapeutics Inc. does not currently have major customers that purchase its therapeutic products. Its business model at this stage involves research, development, and strategic partnerships rather than commercial sales to individuals or other companies (such as hospitals, pharmacies, or distributors).
Therefore, Decoy Therapeutics Inc. does not have major customers to list at this time.
AI Analysis | Feedback
HLB Life Sciences (079430)
AI Analysis | Feedback
Rick Pierce, Chief Executive Officer
Mr. Pierce co-founded Decoy Therapeutics in 2020 and has served as its Chief Executive Officer and director since its inception. He has over 20 years of senior leadership and operating experience in building successful biotechnology companies. From September 2022 to November 2024, Mr. Pierce was an executive officer of Innovation1 Biotech, Inc., a drug discovery company. He also served as a Senior Advisor for Bionest Partners, a life sciences consulting company, from 2017 to 2020. Mr. Pierce is an advisor to the Canadian Consulate of Boston/Cambridge’s Healthcare and Technology Accelerator and a board member of the Canadian Entrepreneurs of New England, where he chairs the Life Sciences Leadership Council.
Mark Rosenblum, Chief Financial Officer
Mr. Rosenblum was the Chief Financial Officer of Salarius Pharmaceuticals and continued in this role for the combined company, Decoy Therapeutics, following the merger. He was also appointed as the acting Chief Executive Officer of Salarius Pharmaceuticals in August 2025 as the company finalized its merger with Decoy Therapeutics Inc. Prior to joining Salarius as a financial consultant to assist with a previous merger, Mr. Rosenblum served as Chairman and Chief Executive Officer of ActiveCare, Inc., a publicly traded healthcare company, and has held Chief Financial Officer positions at several publicly traded companies. He holds a Masters in Accountancy and a B.S.
Barbara Hibner, Chief Scientific Officer
Dr. Hibner co-founded Decoy Therapeutics in 2020 and has served as its Chief Scientific Officer, Director, and Board Chair since then. From January 2017 to April 2020, she co-founded and was Chief Executive Officer of PercepTx, a company focused on targeted cancer immunotherapy utilizing computational modeling and quantitative pharmacology for antibody drug conjugates. Before that, Dr. Hibner held various scientific and managerial roles in discovery, pharmacology, and research quality at Bayer. Her contributions include work that led to the approval of two small molecule drugs, sorafenib and ixazomib.
Peter Marschel, Chief Business Officer
Mr. Marschel co-founded Decoy Therapeutics in 2020 and has been its Chief Business Officer and director since then. Previously, until April 2020, he co-founded and served as Chief Financial Officer of PercepTx, a targeted cancer immunotherapy accelerator that focused on leveraging computational modeling and quantitative pharmacology to enhance the value of preclinical monoclonal antibody-based therapeutic assets. He holds an MSA and an MBA.
Michael Lipp, Chief Technology Officer
Dr. Lipp is a co-founder of Decoy Therapeutics. He holds a PhD.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
For Decoy Therapeutics Inc. (DCOY), previously Salarius Pharmaceuticals, Inc., the expected drivers of future revenue growth over the next 2-3 years are primarily centered on advancing its innovative peptide conjugate therapeutics platform and pipeline through strategic collaborations and funding, given its preclinical stage.
- Advancement of Pipeline Candidates through Strategic Partnerships: Decoy Therapeutics's focus on developing novel peptide conjugate therapeutics, particularly its lead antiviral programs targeting respiratory viruses like pan-coronavirus, flu, COVID-19, and RSV, and candidates for GI cancers, is a key driver. As these preclinical programs successfully advance into and through early clinical stages, the company is likely to secure milestone payments from existing or new strategic development partners.
- New Strategic Collaborations and Licensing Agreements: The company's proprietary IMP3ACT platform, which leverages machine learning and AI for designing and manufacturing peptide conjugates, presents a significant opportunity for revenue growth. Forming additional strategic partnerships or licensing agreements with larger pharmaceutical companies to co-develop specific drug candidates or to license the platform technology itself could generate upfront payments, research funding, and future milestone payments.
- Increased Non-Dilutive Funding and Grants: Decoy Therapeutics has already secured significant non-dilutive capital, including a Global Access Commitment Agreement with the Gates Foundation to fund the development of a globally accessible manufacturing platform for antiviral therapeutics, and funding support from Google AI startup program and NVIDIA Inception program. Continued and expanded non-dilutive funding from such foundations and governmental agencies like the Biomedical Advanced Research and Development Authority (BARDA) for its antiviral development efforts will contribute directly to its financial resources and R&D capabilities, impacting its revenue over the next 2-3 years.
AI Analysis | Feedback
Share Issuance
- Decoy Therapeutics implemented a 1-for-12 reverse stock split effective March 6, 2026, reducing outstanding shares from approximately 6.38 million to 532,000, primarily to regain compliance with Nasdaq's minimum bid price requirement.
- Shareholders approved the Decoy Therapeutics 2026 Equity Incentive Plan on February 25, 2026.
- Shareholders have experienced substantial dilution over the past year, with total shares outstanding growing by 5442.4%, and the company previously conducted a 1-for-15 reverse stock split on August 18, 2025.
Inbound Investments
- Decoy Therapeutics entered into a Global Access Commitment Agreement with the Bill & Melinda Gates Foundation in January 2026 to develop a globally accessible manufacturing platform for peptide-conjugate antivirals.
Capital Expenditures
- Decoy Therapeutics has reported minimal or no significant capital expenditures in recent years, with some financial statements indicating $0 for certain periods.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 19.85 |
| Mkt Cap | 59.5 |
| Rev LTM | 0 |
| Op Inc LTM | -5 |
| FCF LTM | -4 |
| FCF 3Y Avg | 985 |
| CFO LTM | -4 |
| CFO 3Y Avg | 1,197 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.1% |
| Rev Chg 3Y Avg | 9.9% |
| Rev Chg Q | 7.8% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | 541.0% |
| Op Inc Chg 3Y Avg | 176.3% |
| Op Mgn LTM | 38.2% |
| Op Mgn 3Y Avg | 24.1% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 34.7% |
| CFO/Rev 3Y Avg | 21.5% |
| FCF/Rev LTM | 30.4% |
| FCF/Rev 3Y Avg | 17.7% |
Segment Financials
Revenue by Segment| $ Mil | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Developing treatments for cancers caused by dysregulated gene expression | 2 | 5 | 3 | 1 | |
| Consumer Operations | 1 | ||||
| Corporate | 0 | ||||
| Drug Development | 0 | ||||
| Total | 2 | 5 | 3 | 1 | 1 |
| $ Mil | 2025 | 2024 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Developing treatments for cancers caused by dysregulated gene expression | -13 | -6 | -2 | ||
| Corporate | -8 | -9 | -10 | ||
| Drug Development | -12 | -17 | -20 | ||
| Consumer Operations | -9 | -10 | |||
| Total | -13 | -6 | -22 | -35 | -40 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Developing treatments for cancers caused by dysregulated gene expression | -13 | -6 |
| Total | -13 | -6 |
| $ Mil | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Developing treatments for cancers caused by dysregulated gene expression | 7 | 15 | 41 | 25 |
| Total | 7 | 15 | 41 | 25 |
Price Behavior
| Market Price | $6.00 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 01/08/2026 | |
| Distance from 52W High | -97.2% | |
| 50 Days | 200 Days | |
| DMA Price | $6.11 | $17.61 |
| DMA Trend | down | down |
| Distance from DMA | -1.9% | -65.9% |
| 3M | 1YR | |
| Volatility | 95.8% | 145.0% |
| Downside Capture | 131.34 | 340.47 |
| Upside Capture | 12.23 | -145.56 |
| Correlation (SPY) | 10.4% | 11.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.64 | -0.47 | 0.95 | 1.75 | 0.94 | -0.04 |
| Up Beta | -5.13 | -1.33 | -1.08 | 0.83 | 1.30 | -1.52 |
| Down Beta | 0.34 | -0.01 | 2.52 | 3.80 | 2.49 | 1.64 |
| Up Capture | 387% | 110% | 131% | 113% | -54% | -6% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 9 | 20 | 28 | 56 | 102 | 311 |
| Down Capture | -427% | -225% | 144% | 184% | 175% | 106% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 11 | 21 | 34 | 66 | 146 | 421 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DCOY | |
|---|---|---|---|---|
| DCOY | -97.1% | 144.9% | -1.71 | - |
| Sector ETF (XLV) | 16.9% | 15.1% | 0.83 | 2.6% |
| Equity (SPY) | 24.6% | 12.5% | 1.48 | 12.0% |
| Gold (GLD) | 21.8% | 27.6% | 0.70 | 2.2% |
| Commodities (DBC) | 16.7% | 18.8% | 0.69 | -3.5% |
| Real Estate (VNQ) | 12.3% | 13.8% | 0.60 | 10.3% |
| Bitcoin (BTCUSD) | -38.0% | 42.5% | -1.01 | 15.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DCOY | |
|---|---|---|---|---|
| DCOY | -83.1% | 142.0% | -0.65 | - |
| Sector ETF (XLV) | 5.8% | 14.8% | 0.21 | 1.4% |
| Equity (SPY) | 13.1% | 17.1% | 0.59 | 4.2% |
| Gold (GLD) | 16.8% | 18.3% | 0.74 | -1.8% |
| Commodities (DBC) | 7.3% | 19.4% | 0.28 | 1.3% |
| Real Estate (VNQ) | 2.4% | 18.9% | 0.03 | 5.4% |
| Bitcoin (BTCUSD) | 9.7% | 54.1% | 0.38 | 2.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DCOY | |
|---|---|---|---|---|
| DCOY | -82.8% | 133.1% | -0.55 | - |
| Sector ETF (XLV) | 9.8% | 16.6% | 0.48 | 7.2% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 8.9% |
| Gold (GLD) | 11.9% | 16.1% | 0.61 | -1.0% |
| Commodities (DBC) | 5.9% | 18.0% | 0.25 | 4.4% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 9.6% |
| Bitcoin (BTCUSD) | 57.0% | 66.5% | 0.97 | 4.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/10/2023 | -5.9% | 27.6% | 22.0% |
| 11/10/2022 | 3.8% | 17.4% | 0.0% |
| 8/15/2022 | 2.2% | -6.7% | -8.2% |
| 5/12/2022 | -15.4% | -11.2% | -12.2% |
| 3/10/2022 | -26.6% | -21.9% | -25.7% |
| 8/5/2021 | 6.6% | 9.9% | 40.8% |
| 8/12/2020 | -4.7% | -4.7% | -21.2% |
| SUMMARY STATS | |||
| # Positive | 3 | 3 | 3 |
| # Negative | 4 | 4 | 4 |
| Median Positive | 3.8% | 17.4% | 22.0% |
| Median Negative | -10.6% | -8.9% | -16.7% |
| Max Positive | 6.6% | 27.6% | 40.8% |
| Max Negative | -26.6% | -21.9% | -25.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/10/2023 | -5.9% | 27.6% | 22.0% |
| 11/10/2022 | 3.8% | 17.4% | 0.0% |
| 8/15/2022 | 2.2% | -6.7% | -8.2% |
| 5/12/2022 | -15.4% | -11.2% | -12.2% |
| 3/10/2022 | -26.6% | -21.9% | -25.7% |
| 8/5/2021 | 6.6% | 9.9% | 40.8% |
| 8/12/2020 | -4.7% | -4.7% | -21.2% |
| SUMMARY STATS | |||
| # Positive | 3 | 3 | 3 |
| # Negative | 4 | 4 | 4 |
| Median Positive | 3.8% | 17.4% | 22.0% |
| Median Negative | -10.6% | -8.9% | -16.7% |
| Max Positive | 6.6% | 27.6% | 40.8% |
| Max Negative | -26.6% | -21.9% | -25.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/21/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/22/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/27/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/21/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/22/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/27/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/25/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/12/2021 | 10-Q |
| 12/31/2020 | 03/18/2021 | 10-K |
| 09/30/2020 | 11/12/2020 | 10-Q |
| 06/30/2020 | 08/12/2020 | 10-Q |
| 03/31/2020 | 05/14/2020 | 10-Q |
| 12/31/2019 | 03/23/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
| 06/30/2019 | 07/17/2019 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.